Clinical Trial Update: Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy, safety, and tolerability of BAF312 versus placebo in patients with intracerebral hemorrhage (ICH) has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Stroke
• Intracerebral Hemorrhage

Drugs mentioned

• BAF312 (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH) | Phase 2 | Status: COMPLETED | Results posted: 2021-06-07